organization · Reporting owner

INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.

Disclosed activity across 2 companies

Tapewire entity: 163336
SEC CIK: 0001172861

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ENTELLUS MEDICAL INCENTL · Entity 16119	10% owner	January 31, 2017	February 02, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ENTELLUS MEDICAL INC

Report date January 31, 2017 · Filed February 02, 2017

Jointly reported with SVLSF IV, LLC, INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P., INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P., SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P., SV LIFE SCIENCES FUND IV, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivative	IndirectBy ILSF LP1	1,091,166	Reported balance After 2017-01-31 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-01-31 · Sale · Disposed 220,431 · Balance 1,091,166 F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein.
Common Stock, $0.001 par valueSEC Table I · non-derivative	IndirectBy ILSF Co-Invest	12,947	Reported balance After 2017-01-31 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2017-01-31 · Sale · Disposed 2,615 · Balance 12,947 F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein.
Common Stock, $0.001 par valueSEC Table I · non-derivative	IndirectBy ILSF Strategic	10,424	Reported balance After 2017-01-31 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2017-01-31 · Sale · Disposed 2,106 · Balance 10,424 F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein.
Common Stock, $0.001 par valueSEC Table I · non-derivative	IndirectBy Fund IV	1,791,070	Reported balance After 2017-01-31 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2017-01-31 · Sale · Disposed 299,424 · Balance 1,791,070 F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F4: SV Life Sciences Fund IV (GP), L.P. ("Fund IV GP") is the general partner of each of SV Life Sciences Fund IV, L.P. ("Fund IV") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Fund IV Strategic" and together with Fund IV, the "Fund IV Entities"). SVLSF IV, LLC (the "SVLS General Partner") is the general partner of Fund IV GP and, through an investment committee comprised of David Milne (also a member of the Issuer's board of directors), James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund IV Entities by a majority vote. F5: Each member of the investment committee of SVLS General Partner disclaims beneficial ownership over the Shares held by the Fund IV Entities except to the extent of any pecuniary interest therein. Each of SVLS General Partner and Fund IV GP disclaim beneficial ownership over the Shares held by the Fund IV Entities except to the extent of their respective pecuniary interest therein.
Common Stock, $0.001 par valueSEC Table I · non-derivative	IndirectBy Fund IV Strategic	50,849	Reported balance After 2017-01-31 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2017-01-31 · Sale · Disposed 8,501 · Balance 50,849 F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F4: SV Life Sciences Fund IV (GP), L.P. ("Fund IV GP") is the general partner of each of SV Life Sciences Fund IV, L.P. ("Fund IV") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Fund IV Strategic" and together with Fund IV, the "Fund IV Entities"). SVLSF IV, LLC (the "SVLS General Partner") is the general partner of Fund IV GP and, through an investment committee comprised of David Milne (also a member of the Issuer's board of directors), James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund IV Entities by a majority vote. F5: Each member of the investment committee of SVLS General Partner disclaims beneficial ownership over the Shares held by the Fund IV Entities except to the extent of any pecuniary interest therein. Each of SVLS General Partner and Fund IV GP disclaim beneficial ownership over the Shares held by the Fund IV Entities except to the extent of their respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017.

F2: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote.

F3: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein.

F4: SV Life Sciences Fund IV (GP), L.P. ("Fund IV GP") is the general partner of each of SV Life Sciences Fund IV, L.P. ("Fund IV") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Fund IV Strategic" and together with Fund IV, the "Fund IV Entities"). SVLSF IV, LLC (the "SVLS General Partner") is the general partner of Fund IV GP and, through an investment committee comprised of David Milne (also a member of the Issuer's board of directors), James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund IV Entities by a majority vote.

F5: Each member of the investment committee of SVLS General Partner disclaims beneficial ownership over the Shares held by the Fund IV Entities except to the extent of any pecuniary interest therein. Each of SVLS General Partner and Fund IV GP disclaim beneficial ownership over the Shares held by the Fund IV Entities except to the extent of their respective pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

SUTRO BIOPHARMA, INC.

Report date September 27, 2018 · Filed October 01, 2018

Jointly reported with SVLSF V, LLC, ILSF III, LLC, INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P., INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P., INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P., SV Life Sciences Fund V (GP), LP, SV LIFE SCIENCES FUND V LP, SV Life Sciences Fund V Strategic Partners, L.P.

Section 16 reporting ended · disclosed 2018-10-01. Current position is not established by this disclosure.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

F2: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein.

F3: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F4: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F5: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F6: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F7: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F8: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

F9: The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised.

F10: Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries E Preferred Stock · Derivative	193,492	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 36 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 5,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F7 · derivative.exercise_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F7 · derivative.expiration_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries D Preferred Stock · Derivative	141,249	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 35 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 5,721 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries C Preferred Stock · Derivative	194,786	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 34 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 7,207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries E Preferred Stock · Derivative	9,155,794	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 33 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 251,783 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F7 · derivative.exercise_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F7 · derivative.expiration_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries D Preferred Stock · Derivative	6,683,697	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 32 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 270,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries C Preferred Stock · Derivative	9,217,015	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 31 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 341,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries C Preferred Stock · Derivative	52,183	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 30 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries B Preferred Stock · Derivative	106,019	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 29 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 6,128 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries A Preferred Stock · Derivative	17,533	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 28 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries C Preferred Stock · Derivative	5,462,550	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 27 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 0 Underlying: Common Stock · 202,115 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries B Preferred Stock · Derivative	11,097,596	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 26 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 0 Underlying: Common Stock · 641,440 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries A Preferred Stock · Derivative	1,835,270	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 25 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 0 Underlying: Common Stock · 79,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries C Preferred Stock · Derivative	64,815	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 24 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,399 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries B Preferred Stock · Derivative	131,683	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 23 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 0 Underlying: Common Stock · 7,610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionSeries A Preferred Stock · Derivative	21,776	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 22 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 0 Underlying: Common Stock · 943 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	5,320	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 15 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 18,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	5,721	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 14 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 12,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	7,207	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 13 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 7,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	251,783	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 12 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 863,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	270,690	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 11 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 611,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	341,030	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 10 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 341,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	1,931	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 9 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 8,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	6,128	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 8 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 6,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	758	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 7 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	202,115	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 6 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 923,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	641,440	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 5 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 720,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	79,467	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 4 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 79,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	2,399	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 3 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 10,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	7,610	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 2 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 8,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
October 01, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	ConversionCommon Stock	943	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 1 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
September 27, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	Exercise / conversionSeries C Preferred Stock · Derivative	4,978	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 21 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners L.P. Disclosed balance after: 52,183 Underlying: Common Stock · 184 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date. F10 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date. F10 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
September 27, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	Exercise / conversionSeries C Preferred Stock Warrant (right to buy) · Derivative	4,978	$0.00 Strike: $0.48	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 20 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners L.P. Disclosed balance after: 4,315 Underlying: Series C Preferred Stock · 4,978 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised. F9 · derivative.expiration_date: The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
September 27, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	Exercise / conversionSeries C Preferred Stock · Derivative	521,159	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 19 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LPI) L.P. Disclosed balance after: 5,462,550 Underlying: Common Stock · 19,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date. F10 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date. F10 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
September 27, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	Exercise / conversionSeries C Preferred Stock Warrant (right to buy) · Derivative	521,159	$0.00 Strike: $0.48	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 18 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LPI) L.P. Disclosed balance after: 451,869 Underlying: Series C Preferred Stock · 521,159 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised. F9 · derivative.expiration_date: The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
September 27, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	Exercise / conversionSeries C Preferred Stock · Derivative	6,183	$0.00	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 17 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 64,815 Underlying: Common Stock · 228 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date. F10 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date. F10 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
September 27, 2018 Filed Oct 1, 2018 17:28 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	Exercise / conversionSeries C Preferred Stock Warrant (right to buy) · Derivative	6,183	$0.00 Strike: $0.48	$0.00	Disclosure SEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 16 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 5,361 Underlying: Series C Preferred Stock · 6,183 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised. F9 · derivative.expiration_date: The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document
January 31, 2017 Filed Feb 2, 2017 16:10 UTC	ENTELLUS MEDICAL INC ENTL · Entity 16119	SaleCommon Stock, $0.001 par value	8,501	$17.00	$144,517.00	Disclosure SEC source: 0001235802-17-000022 · primary_doc.xml · nonDerivative · entry 5 SVLSF IV, LLC · CIK 0001422339 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund IV Strategic Disclosed balance after: 50,849 F1 · price: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F4 · ownership.nature: SV Life Sciences Fund IV (GP), L.P. ("Fund IV GP") is the general partner of each of SV Life Sciences Fund IV, L.P. ("Fund IV") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Fund IV Strategic" and together with Fund IV, the "Fund IV Entities"). SVLSF IV, LLC (the "SVLS General Partner") is the general partner of Fund IV GP and, through an investment committee comprised of David Milne (also a member of the Issuer's board of directors), James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund IV Entities by a majority vote. F5 · ownership.nature: Each member of the investment committee of SVLS General Partner disclaims beneficial ownership over the Shares held by the Fund IV Entities except to the extent of any pecuniary interest therein. Each of SVLS General Partner and Fund IV GP disclaim beneficial ownership over the Shares held by the Fund IV Entities except to the extent of their respective pecuniary interest therein. Read SEC document
January 31, 2017 Filed Feb 2, 2017 16:10 UTC	ENTELLUS MEDICAL INC ENTL · Entity 16119	SaleCommon Stock, $0.001 par value	299,424	$17.00	$5,090,208.00	Disclosure SEC source: 0001235802-17-000022 · primary_doc.xml · nonDerivative · entry 4 SVLSF IV, LLC · CIK 0001422339 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund IV Disclosed balance after: 1,791,070 F1 · price: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F4 · ownership.nature: SV Life Sciences Fund IV (GP), L.P. ("Fund IV GP") is the general partner of each of SV Life Sciences Fund IV, L.P. ("Fund IV") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Fund IV Strategic" and together with Fund IV, the "Fund IV Entities"). SVLSF IV, LLC (the "SVLS General Partner") is the general partner of Fund IV GP and, through an investment committee comprised of David Milne (also a member of the Issuer's board of directors), James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund IV Entities by a majority vote. F5 · ownership.nature: Each member of the investment committee of SVLS General Partner disclaims beneficial ownership over the Shares held by the Fund IV Entities except to the extent of any pecuniary interest therein. Each of SVLS General Partner and Fund IV GP disclaim beneficial ownership over the Shares held by the Fund IV Entities except to the extent of their respective pecuniary interest therein. Read SEC document
January 31, 2017 Filed Feb 2, 2017 16:10 UTC	ENTELLUS MEDICAL INC ENTL · Entity 16119	SaleCommon Stock, $0.001 par value	2,106	$17.00	$35,802.00	Disclosure SEC source: 0001235802-17-000022 · primary_doc.xml · nonDerivative · entry 3 SVLSF IV, LLC · CIK 0001422339 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ILSF Strategic Disclosed balance after: 10,424 F1 · price: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2 · ownership.nature: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3 · ownership.nature: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein. Read SEC document
January 31, 2017 Filed Feb 2, 2017 16:10 UTC	ENTELLUS MEDICAL INC ENTL · Entity 16119	SaleCommon Stock, $0.001 par value	2,615	$17.00	$44,455.00	Disclosure SEC source: 0001235802-17-000022 · primary_doc.xml · nonDerivative · entry 2 SVLSF IV, LLC · CIK 0001422339 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ILSF Co-Invest Disclosed balance after: 12,947 F1 · price: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2 · ownership.nature: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3 · ownership.nature: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein. Read SEC document
January 31, 2017 Filed Feb 2, 2017 16:10 UTC	ENTELLUS MEDICAL INC ENTL · Entity 16119	SaleCommon Stock, $0.001 par value	220,431	$17.00	$3,747,327.00	Disclosure SEC source: 0001235802-17-000022 · primary_doc.xml · nonDerivative · entry 1 SVLSF IV, LLC · CIK 0001422339 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. · CIK 0001392309 · 10% owner SV LIFE SCIENCES FUND IV, L.P. · CIK 0001367381 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ILSF LP1 Disclosed balance after: 1,091,166 F1 · price: Represents a public offering price of $17.00 per share before underwriting discounts and commissions pursuant to an Underwriting Agreement dated January 25, 2017, which offering closed on January 31, 2017. F2 · ownership.nature: International Life Sciences Fund III (GP), L.P. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. F3 · ownership.nature: Each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Each of ILSF General Partner and Fund III GP disclaim beneficial ownership over the Shares held by the Fund III Entities except to the extent of their respective pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.